Silo Pharma files provisional patent for ketamine pain management (SP-26) targeting fibromyalgia.

Silo Pharma, Inc.

Provisional patent titled 'Methods and Compositions for Pain Management' covers chronic pain including fibromyalgia.
Fibromyalgia affects approximately 2% of the U.S. population; initially targeted indication for company drug SP-26.
Company is working towards submitting an IND package to FDA under 505(b)(2) regulatory pathway for SP-26.
CEO Eric Weisblum states patent supports multi-pronged strategy to advance SP-26 into the clinic.
Silo Pharma holds over six issued and provisional patents in rare disease space.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.